Advancing Basic and Translational Science: Highlights From the Basic Science Workshop at the GRAPPA 2023 Annual Meeting

J Rheumatol. 2024 Oct 1;51(Suppl 2):84-88. doi: 10.3899/jrheum.2024-0459.

Abstract

Contemporary translational and clinical research advances in psoriatic disease (PsD) were highlighted at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting basic science workshop. This year's workshop focused on key topics, including the significance of the annual GRAPPA meetings as a platform for collaboration and knowledge exchange. Discussions centered around expanding our understanding of tumor necrosis factor inhibitor (TNFi) treatment in PsD and enhancing early detection strategies for PsD comorbidities, specifically for the timely intervention and management of cardiovascular (CV) comorbidities. Insights on the role of the C-C chemokine receptor type 6 (CCR6) in PsD and psoriatic arthritis were provided, suggesting that blockade of CCR6 can reduce psoriasis-like dermatitis and joint inflammation in mouse models.

Keywords: GRAPPA; animal models; basic research; psoriasis; psoriatic arthritis.

MeSH terms

  • Animals
  • Arthritis, Psoriatic* / drug therapy
  • Humans
  • Psoriasis* / drug therapy
  • Translational Research, Biomedical
  • Translational Science, Biomedical
  • Tumor Necrosis Factor Inhibitors / therapeutic use

Substances

  • Tumor Necrosis Factor Inhibitors